Research Reports

Key takeaways

Brian J. Kieser and Kevin M. Harris appointed to NexGel board on May 6, 2026, term expires at next annual meeting.

No compensation for board appointments; standard non-employee director pay applies.

Mr. Kieser, CEO and indirect sole owner of Sequence LifeScience, received $1M convertible note at $0.60/share and warrant for 833,334 shares at $0.80/share on May 11, 2026.

Sequence previously issued $5.5M convertible notes and warrants in April 2026 tied to Celularity assets acquisition.

Mr. Kieser has indirect interest via Sequence and direct interest in his note; Mr. Harris is Sequence COO with no equity ownership.

Press release issued May 6, 2026, filed as Exhibit 99.1.

Full analysis

The appointments of Brian J. Kieser, CEO of Sequence LifeScience, and Kevin M. Harris, its COO, to NexGel's board strengthen ties with Sequence, which provided $5.5 million in convertible financing linked to the Celularity assets acquisition. Mr. Kieser's additional $1 million personal investment on substantially identical terms underscores alignment with the company's growth strategy in healthcare products. Both appointees bring extensive experience in biomedical innovation, regenerative biologics, and financial management, potentially aiding expansion of NexGel's hydrogel portfolio and new acquisitions. No immediate departures or other officer changes disclosed.

NXGLW · NEXGEL, Inc.

Summary

Key takeaways

Full analysis